Press release - No 11 / 2018
Zealand Pharma to attend Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018
Copenhagen, 2 May, 2018 - Mats Blom, Executive Vice President and Chief Financial Officer (CFO) of Zealand Pharma, will
be presenting at the Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018.
For further information, please contact:
Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design
and development of innovative peptide-based medicines. Zealand has a late stage clinical portfolio of proprietary product
candidates focusing on specialty gastrointestinal and metabolic diseases. In addition, it has two marketed products, commercialized
by Sanofi, and two product candidates under license collaboration with Boehringer Ingelheim.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please
visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
